Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

MRKRBullishResearch Analysisnews

High materiality8/10

Marker Therapeutics Stock Drops After Report About Lymphoma Treatment

Aug 26, 2025, 12:57 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The positive response rates and safety profile may attract investor interest, similar to past biotech advancements leading to rebounds after study updates.

AI summary

What happened, with direct paths to the underlying reporting

Marker Therapeutics updated on Phase 1 APOLLO study for MT-601. MT-601 demonstrated a 66% response rate in Non-Hodgkin Lymphoma patients. No dose-limiting toxicities were reported, indicating robust safety. Future updates on clinical data are expected in the first half of 2026. MRKR stock is currently down 14.28%, trading at $1.08.

Marker Therapeutics updated on Phase 1 APOLLO study for MT-601.
MT-601 demonstrated a 66% response rate in Non-Hodgkin Lymphoma patients.
No dose-limiting toxicities were reported, indicating robust safety.
Future updates on clinical data are expected in the first half of 2026.
MRKR stock is currently down 14.28%, trading at $1.08.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.